You just read:

FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Feb 12, 2019, 16:28 ET